A Phase 2 Study of LY573636-sodium Administered as Second-line or Third-line Treatment in Patients with Unresectable or Metastatic Soft Tissue Sarcoma [Estudio fase II de LY573636 sodico administrado como tratamiento de segunda o tercera linea en pacientes con sarcoma de tejido blando irresecable o metastasico]

Trial Profile

A Phase 2 Study of LY573636-sodium Administered as Second-line or Third-line Treatment in Patients with Unresectable or Metastatic Soft Tissue Sarcoma [Estudio fase II de LY573636 sodico administrado como tratamiento de segunda o tercera linea en pacientes con sarcoma de tejido blando irresecable o metastasico]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2011

At a glance

  • Drugs Tasisulam (Primary)
  • Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Acronyms JZAD
  • Sponsors Lilly Espana
  • Most Recent Events

    • 29 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top